SCHEMBL2849167

SCHEMBL2849167

COCC(=O)c1c(CC(=O)O)nn(-c2ccc(F)cc2Cl)c1O

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.35
MARS1 P56192 1/20 0.35
P2RX7 Q99572 10/20 0.34
LMNA P02545 3/20 0.34
ALDH1A1 P00352 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
CNR1 P21554 1/20 0.33
MAPK14 Q16539 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32
CYP2C19 P33261 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1723074 0.91 P2RX7 (0.36) GRM5P2RX7LMNAALDH1A1SMN1; SMN2
SCHEMBL1303913 0.82 CHRM1 (0.35) GRM5MARS1P2RX7LMNAALDH1A1
SCHEMBL2845682 0.81 GRM5 (0.34) GRM5MARS1P2RX7LMNAALDH1A1
SCHEMBL2215912 0.71 PDE4B (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ACNR1
SCHEMBL2846887 0.70 MARS1 (0.41) GRM5MARS1P2RX7LMNAALDH1A1
SCHEMBL1722410 0.67 P2RX7 (0.39) MARS1P2RX7MEN1KMT2ACNR1
SCHEMBL20551758 0.66 SLC34A1 (0.42) LMNAALDH1A1KDM4ECYP1A2MAPT
SCHEMBL1722408 0.65 MARS1 (0.37) MARS1P2RX7LMNACNR1
SCHEMBL1566702 0.65 PDE4B (0.41) P2RX7SMN1; SMN2MAPK14KDM4EHPGD
SCHEMBL1723018 0.65 NPSR1 (0.35) GRM5P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10772891-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2020-09-15 US disclosed
US-20180235976-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2018-08-23 US disclosed
US-9974791-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-05-22 US disclosed
EP-2860179-B1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SUISSE SA (CH) 2018-03-14 EP disclosed
US-20150290208-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2015-10-15 US disclosed
US-9096588-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYOTEX SA (CH) 2015-08-04 US disclosed
EP-2860179-A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GenKyoTex SA (CH) 2015-04-15 EP disclosed
EP-2344492-B1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2014-10-29 EP disclosed
WO-2010035221-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS GENKYOTEX SA (CH) 2010-04-01 WO disclosed
EP-2166010-A1 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors GENKYO TEX SA (CH) 2010-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150290208-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB GRM5 1468/4885MARS1 3708/4885P2RX7 229/4885
US-20180235976-A1 PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS NOX1, NOX4, CYBB GRM5 1468/4885MARS1 3708/4885P2RX7 229/4885
US-10772891-B2 Pyrazolo pyridine derivatives as NADPH oxidase inhibitors NOX1, NOX4, CYBB GRM5 1468/4885MARS1 3708/4885P2RX7 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.